Skip to content
Goldline Pharmaceutical logo

Goldline Pharmaceutical IPO

Check allotment status
Issue price
₹43
Listing price
₹59.75
+38.95%
Current price
₹29.27
-31.93%
Subscribed
781.85x
Issue size
₹12 Cr
Listed on
19 May 2026

IPO timeline

  1. Opens
    12 MayTue
  2. Closes
    14 MayThu
  3. Allotment
    15 MayFri
  4. Refunds
    18 MayMon
  5. Demat credit
    18 MayMon
  6. Listing
    19 MayTue

Issue details

Price band
₹41 – ₹43 per share
Issue size
₹12 Cr
Fresh issue
₹12 Cr · 0.28 Cr shares
Offer for sale
None
Issue type
Fresh capital only
Face value
₹10 per share
Lot size
3,000 shares
Minimum investment
₹1,29,000
Listing on
BSE SME
Exchange code
GLPL.BO · 7716

Lot size and investment

ApplicationLotsSharesAmount
Retail (Min)13,000₹1,29,000
Retail (Max)13,000₹1,29,000
HNI (Min)26,000₹2,58,000

Reservation

QIB
12,72,000 shares (49.65% of the Offer)
NII
3,90,000 shares (15.22% of the Offer)
Retail
9,00,000 shares (35.13% of the Offer)

Allotment status

Registrar: Bigshare Services Private Limited

The allotment for this IPO is final. Check whether you received shares on the registrar's website using your PAN, application number or demat account (DP / Client ID).

Check allotment on Bigshare Services
  1. 1Open the registrar's allotment page and select this IPO from the list.
  2. 2Enter your PAN, application number or DP / Client ID.
  3. 3Submit to see the number of shares allotted, if any.
Basis of allotment
15 May 2026
Refunds initiated
18 May 2026
Shares credited to demat
18 May 2026
Listing
19 May 2026

Grey market premium (GMP)

Updated 18 May 2026, 05:31 PM IST
Current GMP
₹15
+35.00%
Estimated listing price
₹58
Issue price ₹43
Highest
₹25
13 May
Lowest
₹8
8 May

GMP by day (₹ per share)

Day-wise GMP table
DateGMPPremiumEst. listing
18 May 2026₹15+35.00%₹58
17 May 2026₹20+47.00%₹63
15 May 2026₹18+42.00%₹61
14 May 2026₹15+35.00%₹58
13 May 2026₹25+58.00%₹68
12 May 2026₹18+42.00%₹61
11 May 2026₹17+40.00%₹60
10 May 2026₹15+35.00%₹58
9 May 2026₹8+19.00%₹51
8 May 2026₹8+19.00%₹51
Kostak rate
₹0

GMP is an unofficial indicator from an unregulated market. It is shown for information only and is not a prediction of the listing price or a recommendation to apply.

Subscription status

Updated 14 May 2026, 05:10 PM IST
Overall subscription
781.85x
Fully subscribed
  • QIB180.22x
  • NII (HNI)1,227.9x
  • Retail881.15x
CategoryShares offeredShares bid forSubscribed
Qualified Institutional Buyers (QIB)5,40,0009,73,17,000180.22x
Non-Institutional Investors (NII)5,28,00064,83,33,0001,227.9x
bNII — bids above ₹10 Lakh2,58,00051,88,74,0002,011.14x
sNII — bids ₹2 Lakh to ₹10 Lakh1,32,00012,94,59,000980.75x
Retail Individual Investors (RII)9,00,00079,30,38,000881.15x
Total19,68,0001,53,86,88,000781.85x

Financials

Amounts in Rs. Crore
P/E Ratio
13.93
EPS (₹)
3.09
RoCE
38.45%
RoNW
27.37%
PAT Margin
10.09%

Separate pre- and post-issue P/E are not available for this IPO; the P/E shown is as disclosed for the issue.

Period ended31 Dec 202531 Mar 202531 Mar 202431 Mar 2023
Assets27.4026.2822.9319.39
Total Income21.4128.0623.5719.85
Profit After Tax2.222.831.810.26
EBITDA4.165.834.302.19
NET Worth12.3610.357.865.89
Reserves and Surplus3.651.653.762.08
Total Borrowing9.4711.0311.1310.83
CompanyIssue sizeP/ERoNWPAT marginSubscribedListing gain
Goldline Pharmaceutical
This IPO
₹12 Cr13.9327.37%10.09%781.85x+38.95%
Himalaya Nutravedics India
SME · listed 29 Sep 2026
₹26.5 Cr12.6345.12%17.16%2.24x+11.32%
Speciality Medicines
SME · listed 30 Mar 2026
₹29 Cr10.4928.30%14.77%2.19x0.00%
Avience Biomedicals
SME · listed 25 Jun 2026
₹30.24 Cr16.5649.89%15.86%385.4x+90.00%
ABH Healthcare
SME · listed 1 Sep 2026
₹34.98 Cr20.6939.07%10.74%1.42x-2.94%
Bio Medica Laboratories
SME · listed 29 May 2026
₹52 Cr13.4599.59%25.64%2.31x-20.00%
Pramodini Medicare
SME · listed 19 Aug 2026
₹69.04 Cr14.9732.69%27.90%3.66x+1.69%

Peers are other recent IPOs from the same industry, closest in issue size. Ratios are as disclosed at the time of each issue. This is not the listed-peer table from the offer document.

IPO objectives

₹8.9 Cr total

How Goldline Pharmaceutical plans to use the money raised, as stated in the offer document.

  1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company₹8.9 Cr
  2. General corporate purposes

About Goldline Pharmaceutical

Goldline Pharmaceutical Limited was established in 2005 and is engaged in the marketing and distribution of pharmaceutical formulations across India. The company has built its presence through a wide portfolio of healthcare products catering to multiple therapeutic segments. Over the years, Goldline has expanded its distribution network and strengthened relationships with doctors, distributors, and healthcare professionals. The company is promoted by experienced industry professionals who focus on expanding the brand presence and improving market reach in the domestic pharmaceutical sector. The company offers products across general medicine, antibiotics, cardiology, diabetology, gynecology, pediatrics, and wellness categories. Goldline Pharmaceutical mainly follows an asset-light business model, where manufacturing is outsourced to third-party pharma manufacturers while the company focuses on branding, marketing, and distribution activities. This model helps reduce capital expenditure and improve scalability. The company’s operations are mainly based in Nagpur, Maharashtra, with a growing presence across multiple Indian states through its marketing and sales network.

Strengths

  • Asset-light business model reduces manufacturing costs and improves operational scalability significantly.
  • Diversified pharmaceutical portfolio caters to multiple therapeutic and healthcare treatment segments.
  • Strong doctor and distributor network supports consistent product demand across regions.
  • Experienced promoters with pharmaceutical industry knowledge help drive business expansion plans.

Risks

  • Dependence on third-party manufacturers may impact product quality and timely supply.
  • Highly competitive pharmaceutical industry can pressure margins and market share growth.
  • Revenue concentration in domestic markets increases dependence on Indian pharmaceutical demand.
  • Regulatory changes in healthcare sector may affect operations and product approvals.
  • Smaller business scale compared to major pharma companies limits competitive advantages currently.

Promoters and shareholding

Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal

Promoter holding, pre-issue
79.70
Promoter holding, post-issue
57.29%

Registrar, lead managers and documents

Registrar

Bigshare Services Private Limited

8657578989/8069219065/8069219060

ipo@bigshareonline.com

Company contact

103, F-1, Leela Apartment, Shilpa HSG Society, Near Saptagiri Nagar, Shanidham, Narendra Nagar, Nagpur, Maharashtra, 440015

+91 712 2786666

info@goldlinepharma.in

Goldline Pharmaceutical IPO: common questions

1.When does the Goldline Pharmaceutical IPO open and close?

The Goldline Pharmaceutical IPO opens on 12 May 2026 and closes on 14 May 2026.

2.What is the price band of the Goldline Pharmaceutical IPO?

The price band is ₹41 – ₹43 per share, with a lot size of 3,000 shares and a minimum investment of ₹1,29,000.

3.What is the size of the Goldline Pharmaceutical IPO?

The issue size is ₹12 Cr (Fresh capital only).

4.What is the GMP of the Goldline Pharmaceutical IPO?

The last reported grey market premium is ₹15 per share as of 18 May 2026, 05:31 PM IST. GMP is unofficial and changes frequently.

5.When is the Goldline Pharmaceutical IPO allotment?

The basis of allotment is expected on 15 May 2026. Allotment status can be checked with the registrar, Bigshare Services Private Limited.

6.When will the Goldline Pharmaceutical IPO list?

The shares listed on 19 May 2026 on BSE SME.

7.Who is the lead manager of the Goldline Pharmaceutical IPO?

The book running lead manager is Cumulative Capital Pvt. Ltd., and the registrar is Bigshare Services Private Limited.

8.What will the money raised in the Goldline Pharmaceutical IPO be used for?

As stated in the offer document, the proceeds are for: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company; General corporate purposes.

9.How can my company launch an IPO like Goldline Pharmaceutical?

Start with an IPO readiness assessment: eligibility for the NSE Emerge or BSE SME platform, audited financials, governance, conversion to a public limited company and an indicative valuation. Be IPO Ready advises promoters through each step, from readiness to listing day.

For business owners

Your company could be the next listing

Businesses like these raise growth capital on the public markets every week. Tell us about yours and our advisors will tell you, plainly, whether an IPO is within reach and what it would take.

  • Eligibility check against NSE Emerge, BSE SME and Main Board norms
  • Indicative valuation and issue size for your business
  • A clear timeline from readiness to listing day

Check if your business can list

Fill in the eligibility form and get an assessment of where you stand. It takes about five minutes.

Prefer to talk? Call +91 92130 20393